Axogen, Inc. To Host Analyst & Investor Day on March 4th
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has announced its upcoming Analyst & Investor Day scheduled for March 4, 2025, from 9am to 12pm Eastern time.
The event will feature presentations from key leadership including Chief Executive Officer Michael Dale, Chief Financial Officer Nir Naor, and other senior team members. Attendees can expect comprehensive insights into Axogen's business overview, strategic initiatives, growth plans, financial results, and future objectives.
For those unable to attend in person, a live webcast will be available on Axogen's investor relations website under "Axogen Virtual Analyst & Investor Day." A replay of the webcast will remain accessible for 90 days following the event.
Axogen, Inc. (NASDAQ: AXGN), un leader globale nello sviluppo e nella commercializzazione di soluzioni chirurgiche innovative per le lesioni dei nervi periferici, ha annunciato il suo prossimo Analyst & Investor Day previsto per il 4 marzo 2025, dalle 9:00 alle 12:00 ora orientale.
L'evento presenterà interventi da parte dei principali leader, tra cui l'Amministratore Delegato Michael Dale, il Direttore Finanziario Nir Naor e altri membri senior del team. I partecipanti possono aspettarsi approfondimenti completi sulla panoramica aziendale di Axogen, iniziative strategiche, piani di crescita, risultati finanziari e obiettivi futuri.
Per coloro che non possono partecipare di persona, sarà disponibile un webcast dal vivo sul sito web delle relazioni con gli investitori di Axogen, sotto
Axogen, Inc. (NASDAQ: AXGN), un líder global en el desarrollo y comercialización de soluciones quirúrgicas innovadoras para lesiones de nervios periféricos, ha anunciado su próximo Día de Analistas e Inversores programado para el 4 de marzo de 2025, de 9 a.m. a 12 p.m. hora del Este.
El evento contará con presentaciones de líderes clave, incluyendo a Michael Dale, Director Ejecutivo, Nir Naor, Director Financiero y otros miembros senior del equipo. Los asistentes pueden esperar información completa sobre la visión general del negocio de Axogen, iniciativas estratégicas, planes de crecimiento, resultados financieros y objetivos futuros.
Para aquellos que no puedan asistir en persona, habrá un webcast en vivo disponible en el sitio web de relaciones con inversores de Axogen bajo
Axogen, Inc. (NASDAQ: AXGN)는 말초 신경 손상에 대한 혁신적인 외과 솔루션 개발 및 마케팅의 글로벌 리더로, 2025년 3월 4일 오전 9시부터 오후 12시(동부 표준시)에 예정된 애널리스트 및 투자자 데이를 발표했습니다.
이 행사에서는 CEO 마이클 데일, CFO 니르 나오르 및 기타 고위 팀원들의 주요 발표가 있을 예정입니다. 참석자들은 Axogen의 비즈니스 개요, 전략적 이니셔티브, 성장 계획, 재무 결과 및 미래 목표에 대한 포괄적인 통찰력을 기대할 수 있습니다.
직접 참석할 수 없는 분들을 위해 Axogen의 투자자 관계 웹사이트에서 실시간 웹캐스트를 제공할 예정이며,
Axogen, Inc. (NASDAQ: AXGN), un leader mondial dans le développement et la commercialisation de solutions chirurgicales innovantes pour les blessures des nerfs périphériques, a annoncé son prochain Journée des Analystes et des Investisseurs prévue pour le 4 mars 2025, de 9h à 12h heure de l'Est.
L'événement comprendra des présentations de dirigeants clés, y compris le PDG Michael Dale, le directeur financier Nir Naor et d'autres membres seniors de l'équipe. Les participants peuvent s'attendre à des informations complètes sur la vue d'ensemble de l'entreprise Axogen, les initiatives stratégiques, les plans de croissance, les résultats financiers et les objectifs futurs.
Pour ceux qui ne peuvent pas assister en personne, un webinaire en direct sera disponible sur le site Web des relations avec les investisseurs d'Axogen sous
Axogen, Inc. (NASDAQ: AXGN), ein globaler Marktführer in der Entwicklung und Vermarktung innovativer chirurgischer Lösungen für periphere Nervenschäden, hat seinen bevorstehenden Analysten- und Investoren-Tag angekündigt, der für den 4. März 2025 von 9 Uhr bis 12 Uhr Eastern Time geplant ist.
Die Veranstaltung wird Präsentationen von wichtigen Führungspersönlichkeiten beinhalten, darunter CEO Michael Dale, CFO Nir Naor und andere Mitglieder des Führungsteams. Die Teilnehmer können umfassende Einblicke in die Geschäftszusammenfassung von Axogen, strategische Initiativen, Wachstumspläne, finanzielle Ergebnisse und zukünftige Ziele erwarten.
Für diejenigen, die nicht persönlich teilnehmen können, wird auf der Investor-Relations-Website von Axogen ein Live-Webcast verfügbar sein unter
- None.
- None.
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern.
Featured speakers will include Chief Executive Officer - Michael Dale, Chief Financial Officer - Nir Naor, and other senior members of the leadership team. During the event, the Axogen team will offer an overview of the business, strategic initiatives and growth plans, and discuss financial results and objectives.
A live webcast of the event will also be available and can be viewed on Axogen’s investor relations website under Axogen Virtual Analyst & Investor Day. After the event, a replay of the webcast will be available for 90 days in the same location.
About Axogen
Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products that are used across two primary application categories: scheduled, non-trauma procedures and emergent trauma procedures. Scheduled procedures are generally characterized as those where a patient is seeking relief from conditions caused by a nerve defect or surgical procedure. These procedures include providing sensation for women seeking breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of painful neuromas, oral and maxillofacial procedures, and nerve decompression. Emergent procedures are generally characterized as procedures resulting from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist either immediately or within a few days following the initial injury.
Axogen’s product portfolio includes Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard Nerve Connector®, a porcine submucosa ECM coaptation aid for tensionless repair of severed peripheral nerves; Axoguard Nerve Protector®, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard HA+ Nerve Protector™, a porcine submucosa ECM base layer coated with a proprietary hyaluronate-alginate gel, a next-generation technology designed to provide short- and long-term protection for peripheral nerve injuries; Avive+ Soft Tissue Matrix™, a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue repair; and Axoguard Nerve Cap®, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Contact: Axogen, Inc. InvestorRelations@axogeninc.com |
FAQ
When is Axogen's (AXGN) Analyst & Investor Day in 2025?
Who will be speaking at AXGN's upcoming Investor Day?
How can investors access Axogen's (AXGN) March 2025 Investor Day remotely?
What topics will be covered during AXGN's March 4th Investor Day?
How long will the replay of AXGN's Investor Day be available?
